<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ALBURX- albumin human solution </strong><br>CSL Behring AG<br></p></div>
<h1>Albumin (Human) 25% Solution <br>AlbuRx<span class="Sup">®</span> 25 </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DL"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">R<span class="Sub">X</span> only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution is a sterile aqueous solution for intravenous administration containing the albumin component of human blood.</p>
<p>This product is prepared from the plasma of US donors.  The product has been produced by alcohol fractionation and has been heated for 10 hours at 60°C for inactivation of infectious agents.  The results of virus validation studies have shown that the manufacturing process, particularly alcohol fractionation, eliminates enveloped and non-enveloped viruses.  Additionally, heat treatment at 60°C for a period of 10 hours efficiently inactivates viruses.  The solution contains 0.14 M (3.2 mg/mL) sodium.  The aluminum content is ≤ 200 mcg/L and the potassium content is ≤ 0.002 M.  The solution is stabilized with 0.02 M sodium N-acetyltryptophanate and 0.02 M sodium caprylate.  The solution contains no preservative.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CLINPHARM"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY<span class="Sup">13,17</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2></h2>
<p class="First">									AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution should not be used as an intravenous nutrient because of the slow breakdown and relatively unfavorable composition of the albumin molecule with respect to its content of essential amino acids.  Oral provision of proteins or an intravenous regimen providing adequate calories and a suitable amino acid mixture are the methods of choice for the treatment of protein <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span> as such, though they do not permit the rapid correction of <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2></h2>
<p class="First">									The binding properties of albumin may provide an indication for its use in severe hemolytic disease of the newborn, where it may lower the plasma concentration of free bilirubin pending an exchange transfusion.  This effect is possibly also relevant in certain cases of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> with rapidly increasing levels of serum bilirubin, particularly in the presence of severe <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2></h2>
<p class="First">									The colloid osmotic or oncotic properties of albumin at this moment constitute the predominant reason for its clinical use.  The rationale for this is the Starling concept of the capillary balance of hydrostatic and oncotic pressure gradients across the capillary walls as the determinant of the fluid – i.e. volume –  distribution between the intravascular and the interstitial compartment.<span class="Sup">16</span>  The two main indications for the use of AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution are therefore a plasma or blood volume deficit and the oncotic deficit resulting from <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>.  The 25% concentration is oncotically equivalent to approximately five times its volume of normal human plasma.  The effective colloid osmotic pressure of the serum proteins depends very largely on the relatively small and numerous albumin molecules, which therefore play a decisive role in the maintenance of the circulating plasma volume.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="USAGE"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="GeneralPrinciples"></a><a name="section-4.1"></a><p></p>
<h2>General Principles<span class="Sup">17</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.1"></a><p></p>
<h3>Volume Deficit</h3>
<p class="First">Since the oncotic pressure of AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution is about four times higher than that of normal human serum, it will expand the plasma volume if interstitial water is available for an inflow through the capillary walls.  However, many patients suffering from an acute volume deficit also have some degree of interstitial <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.  In the absence of hyperhydration, the treatment of an acute volume deficit with AlbuRx<span class="Sup">®</span> 25 should therefore include isotonic electrolyte solutions with an albumin:electrolyte ratio of 1:3 or 1:4.  By contrast, chronic volume deficits have usually been at least partially compensated for by the renal retention of sodium and water with some degree of tissue <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and in these circumstances a trial with AlbuRx<span class="Sup">®</span> 25 only is indicated.  In any case, an <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> of clinically relevant magnitude requires specific treatment, and the metabolic needs of the patient with respect to fluid and electrolytes must be cared for.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="oncotic"></a><a name="section-4.1.2"></a><p></p>
<h3>Oncotic Deficit</h3>
<p class="First">The common causes of <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span> are protein-calorie <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span>, defective absorption in gastro-intestinal disorders, faulty albumin synthesis in chronic <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, increased protein catabolism postoperatively or with <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, and abnormal renal losses of albumin with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span>.  In all these settings, the circulating albumin <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> is initially maintained by a gradual transfer of extravascular albumin to the circulation, and <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span> ensues only when this compensatory potential has been exhausted.  This implies that manifest <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span> is usually accompanied by a hidden extravascular albumin deficit of equal magnitude as the measurable intravascular deficit, which must be allowed for if AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution is infused because of the <span class="product-label-link" type="condition" conceptid="4023793" conceptname="Capillary permeability">capillary permeability</span> of that protein.</p>
<p>The primary sequel of the oncotic deficit resulting from <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span> is a loss of plasma and a gain of interstitial volume with increased lymphatic flow.  As a secondary response, the kidney retains sodium and water which distribute themselves on both sides of the capillary walls and the plasma volume may be returned almost to normal when the interstitial hydrostatic pressure increases sufficiently to compensate for the decrease of the serum oncotic pressure.  This chain of events is accelerated by the infusion of crystalloid fluids.  The plasma volume is maintained at the price of interstitial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.<span class="Sup">2</span></p>
<p>There is some evidence that a serum oncotic pressure near 20 mmHg  – equaling a total serum protein (TSP) concentration of 5.2 g/100 mL –  represents a threshold, below which the risk of complications increases.<span class="Sup">17</span>  The target organs of <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span> include the skin, the lungs, and the intestine.<span class="Sup">10</span>  Cutaneous <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> lowers the oxygen <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> and may thus impair the healing process.<span class="Sup">5</span>  An oncotic deficit favors the development of interstitial <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span><span class="Sup">4</span> and the intestinal accumulation of fluids, which may progress to a <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.<span class="Sup">9</span></p>
<p>Relief of the basic pathology is the definitive mode of therapy for the restoration of the plasma protein content, but this process takes time to become effective, and the rapid correction of a critical oncotic deficit by the administration of AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution – possibly in conjunction with a diuretic –  may therefore be indicated, particularly in high-risk patients who have undergone abdominal, cardiovascular, thoracic, or urologic surgery or who have acute <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>.  In notably catabolic patients, attempts to raise the TSP level above 6 g/100 mL usually prove futile, even with massive doses of Albumin (Human).<span class="Sup">17</span></p>
<p>It is emphasized that whereas AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution may be necessary to prevent or treat the aforementioned acute complications of <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>, it is <span class="Bold">not</span> indicated for treatment of the chronic condition itself.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Specific Indications<span class="Sup">17</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.1"></a><p></p>
<h3>Acute circumstances in which AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution use is usually appropriate</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.1.1"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">Shock</span></h4>
<p class="First">Though electrolyte solutions such as Ringer's lactate and colloid-containing plasma substitutes may be used as an emergency treatment of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution used according to the aforementioned principles has a much longer intravascular half-life and may therefore be preferable.  In addition, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> of clinically relevant magnitude requires specific therapy with red cells.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.1.2"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span></h4>
<p class="First">Immediate therapy during the first 24 hours is directed at the administration of large volumes of crystalloid solutions and lesser amounts of AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution to maintain an adequate plasma volume and protein (colloid) content.  For continuation of therapy beyond 24 hours, larger amounts of AlbuRx<span class="Sup">®</span> 25 and lesser amounts of crystalloid are generally used.<span class="Sup">17</span>  An optimum regimen for the use of Albumin (Human), electrolytes, and fluid in the early treatment of <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> has, however, not yet been established.</p>
<p>With restoration of normal capillary function, a close relationship exists once again between infused Albumin (Human) and resultant increase in plasma oncotic pressure.  A goal should be sought of maintaining a plasma albumin concentration of about 2.5 ±0.5 g/100 mL or a plasma oncotic pressure of 20 mmHg (equivalent to a TSP concentration of 5.2 g/100 mL).<span class="Sup">17</span>  In the presence of extensive granulating <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>, a daily loss of up to 30 g of albumin may continue into the late post-burn period.<span class="Sup">1</span>  Protein-rich oral feedings, or adequate parenteral nutrition should be included in the overall regimen to the fullest possible extent, though such treatment does not permit the rapid correction of an oncotic deficit.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2"></a><p></p>
<h3>Acute circumstances in which AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution use may be appropriate</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2.1"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Adult Respiratory Distress Syndrome</span></h4>
<p class="First">Several factors are usually involved in the development of the state now commonly called the <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">adult respiratory distress syndrome</span>, one of these being a hypoproteinemic <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span>.  If present, this may be corrected by the use of AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution and a diuretic.<span class="Sup">14,17</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2.2"></a><p></p>
<h4>Cardiopulmonary Bypass</h4>
<p class="First">An adequate blood volume during cardiopulmonary bypass can be maintained with crystalloids as the only pump priming fluid, but only at the price of interstitial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.  A commonly employed program is an AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution and crystalloid pump prime adjusted so as to achieve a hematocrit of 20% and a plasma albumin level of 2.5 g/100 mL in the patient, but the level to which either may be lowered safely has not yet been defined.<span class="Sup">17</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2.3"></a><p></p>
<h4>Pre- and postoperative <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">Hypoproteinemia</span></h4>
<p class="First">Patients undergoing major surgery may lose more than half of their circulating albumin <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span><span class="Sup">6,9,15</span>, and complications attributable to an oncotic deficit may occur in such cases, as well as in septic and intensive care patients.  Oncotic therapy with AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution may therefore be indicated in such patients, according to the principles outlined in <span class="Bold"><a href="#oncotic">Oncotic Deficit</a></span>.  Temporary redistribution of protein is usually not an indication for Albumin (Human).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2.4"></a><p></p>
<h4>Third Space Problems of Infectious Origin</h4>
<p class="First">The sequestration of protein-rich fluid during acute <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="439045" conceptname="Mediastinitis">mediastinitis</span> or extensive <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span> may be of sufficient magnitude to require the treatment of a volume or an oncotic deficit with AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution<span class="Sup">3</span>, although this occurrence is relatively rare.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2.5"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">Acute Liver Failure</span></h4>
<p class="First">In <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>, AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution may serve the triple purpose of stabilizing the circulation, correcting an oncotic deficit and binding excessive serum bilirubin.  The therapeutic approach is guided by the individual circumstances.<span class="Sup">17</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2.6"></a><p></p>
<h4>Acute <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrosis</span></h4>
<p class="First">Patients with acute <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span> may prove refractory to cyclophosphamide or steroid therapy and their <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may even be aggravated initially by steroids.  In such cases, a response may be elicited by combining 100 mL of 20–25% Albumin (Human) solution with an appropriate diuretic.  This combination should be repeated daily for about one week, after which the patient may react satisfactorily to drug therapy.<span class="Sup">17</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2.7"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span></h4>
<p class="First">The use of AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution for blood volume support may be indicated if circulatory instability follows the withdrawal of ascitic fluid.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2.8"></a><p></p>
<h4>Red Cell Resuspension Media</h4>
<p class="First">As a rule, the use of Albumin (Human) for resuspending red cells can be dispensed with.  However, in exceptional circumstances such as certain types of exchange transfusions and the use of very large volumes of erythrocyte concentrates and frozen or washed red cells, the addition of AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution to the resuspension medium may be indicated in order to provide sufficient volume and/or avoid excessive <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span> during the subsequent transfusion.  If necessary, 20–25 g or more of Albumin (Human) per liter of red cell suspension should be added as a concentrated solution to the isotonic, electrolyte suspension of erythrocytes immediately before transfusion, the individual dosage depending on the TSP level of the recipient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2.9"></a><p></p>
<h4>Renal Dialysis</h4>
<p class="First">Patients undergoing long-term hemodialysis may need AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution for the treatment of a volume or an oncotic deficit.  As a rule, the initial dose should not exceed 100 mL of a 20–25% solution, and the patients should be carefully observed for signs of a circulatory overload, to which they are particularly sensitive.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.2.10"></a><p></p>
<h4>Hemolytic Disease of the Newborn</h4>
<p class="First">AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution may be indicated in order to bind and thus detoxify free serum bilirubin in severely hemolytic infants pending an exchange transfusion.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2.3"></a><p></p>
<h3>Circumstances in which AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution use is not justified</h3>
<p class="First">For the reasons set forth in sections <span class="Bold"><a href="#CLINPHARM">CLINICAL PHARMACOLOGY</a></span>. and <span class="Bold"><a href="#GeneralPrinciples">General Principles</a></span>, there is no valid reason for the use of AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution as an intravenous nutrient or for treating the stabilized <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span> accompanying chronic cirrhosis, chronic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, protein-losing enteropathy, <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> and <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span>.</p>
<p>If, however, a patient in this category has to cope with a superimposed acute stress, e.g. anesthesia, surgery or major <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the patient's hemodynamic state, oncotic deficit and fluid balance should be carefully assessed and the appropriate steps taken as indicated by the individual circumstances.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">The only specific contraindication to the use of AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution is a history of an incompatibility reaction to Albumin (Human) in the individual recipient (see <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution is made from human plasma.  Products made from human plasma may contain infectious agents, such as viruses, that can cause disease.  The risk that such products will transmit an infectious agent has been extremely reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and by inactivating and/or removing certain viruses through alcohol fractionation and through heat treatment of the product in the final container for 10 hours at 60°C.  Despite these measures, such products can still potentially transmit disease.  A theoretical risk for transmission of Creutzfeldt-Jakob Disease (CJD) is considered extremely remote.  No cases of transmission of viral diseases or CJD have ever been identified for Albumin (Human).  There is also the possibility that unknown infectious agents may be present in such products.  All <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to CSL Behring Pharmacovigilance Department at 1-866-915-6958.  The physician should discuss the risks and benefits of this product with the patient.</p>
<p>Turbid solutions must not be used.  Do not begin administration more than 4 hours after introduction of the administration set.  Partially used bottles must be discarded.  There exists a risk of potentially fatal <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> from the inappropriate use of sterile water for injection as a diluent for AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution.  Acceptable diluents include 0.9% sodium chloride or 5% dextrose in water.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Adequate precautions should be taken against circulatory overload and may include pulmonary auscultation or X-ray as well as monitoring the central venous or pulmonary artery wedge pressure.  Special caution is indicated in patients with stabilized chronic <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.1"></a><p></p>
<h2>Pregnancy Category C</h2>
<p class="First">Animal reproduction studies have not been conducted with AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution.  It is also not known whether AlbuRx<span class="Sup">®</span> 25 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  AlbuRx<span class="Sup">®</span> 25 should be given to a pregnant woman only if clearly needed.  There is, however, no evidence for any contraindication to the use of AlbuRx<span class="Sup">®</span> 25 specifically associated with reproduction, pregnancy or the fetus.</p>
<p>Use an intravenous infusion set suitable for the infusion of blood and blood products.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Since AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution is sterile when coming from the manufacturer, bacterial contamination with the risk of post-infusion <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span> can only occur if the container has been damaged or following puncture of the rubber cap (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>).</p>
<p>Though very rare, non-septic incompatibility reactions including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> following the administration of albumin-containing preparations have been recorded.<span class="Sup">8,11,12,17</span>  A favorable response was observed to the intravenous administration of 50 to 100 mg of prednisolone.<span class="Sup">12 </span> Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA%20"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution must be administered intravenously.  The venipuncture site should not be infected or traumatized, and should be prepared with standard aseptic technique.  The solution is compatible with whole blood or packed red cells as well as the usual electrolyte and carbohydrate solutions intended for intravenous use.  By contrast, it should not be mixed with protein hydrolysates, amino acid mixtures, or solutions containing alcohol.  It is ready for use as contained in the bottle and may be given without regard to the blood group of the recipient.</p>
<p>The dosage of AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution is based on the principles outlined in the section on <span class="Bold"><a href="#USAGE">INDICATIONS AND USAGE</a></span> but should always be adapted to the individual situation.  The quantities required may be underestimated because of hidden extravascular deficits, and the effect of AlbuRx<span class="Sup">®</span> 25 infusion on the serum protein level should therefore be checked by laboratory analysis.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Volume Deficit</h2>
<p class="First">The appropriate AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution dose for the treatment of a volume deficit should be estimated from the recipient's hemodynamic response<span class="Sup">7</span>, supplemented with the established safeguards against a circulatory overload.  In the absence of active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, the total dose should at any rate not exceed the normal circulating albumin <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, i.e. 2 g per kg body weight.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Oncotic Deficit</h2>
<p class="First">The appropriate AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution dose in grams of protein for the correction of an oncotic deficit can, as an average, be estimated from the difference between the desired and the actual TSP level x plasma volume (~40 mL/kg) × 2, the latter factor allowing for the hidden extravascular deficit.  The individual effect is, however, variable and should be checked by measuring the post-infusion TSP level.<span class="Sup">10,17</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>Hemolytic Disease of the Newborn</h2>
<p class="First">The appropriate AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution dose for the binding of free serum bilirubin in severely hemolytic infants is 1 g/kg body weight, to be given about one hour prior to the exchange transfusion, and caution is recommended in hypervolemic infants.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">AlbuRx<span class="Sup">®</span> 25 is supplied as a 25% solution (250 g/L).</p>
<p>Each product presentation includes a package insert and the following components:</p>
<table width="70%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="25%">
<col align="left" valign="top" width="55%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Presentation</th>
<th class="Lrule" align="center">Carton <br>NDC Number</th>
<th class="Lrule Rrule" align="left">Components</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">50 mL</td>
<td class="Lrule" align="center">44206-251-05</td>
<td class="Lrule Rrule" align="left">One vial containing 12.5 grams of albumin<br>[NDC 44206-251-90]</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">100 mL</td>
<td class="Lrule" align="center">44206-251-10</td>
<td class="Lrule Rrule" align="left">One vial containing 25 grams of albumin<br>[NDC 44206-251-91]</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">AlbuRx<span class="Sup">®</span> 25, Albumin (Human) 25% solution should be stored at a temperature not exceeding 30°C (86°F).  It should not be used after the expiration date printed on the label.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Birke G, Liljedahl SO, Plantin LO, Reizenstein P.  <span class="Italics">Acta Chir. Scand</span>.  1968;134:27.</li>
<li>Cervera AL, Moss G.  <span class="Italics">J. <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Trauma</span></span>.  1974;14:506.</li>
<li>Clowes GH Jr, Vucinic M, Weidner MG.  <span class="Italics">Ann. Surg</span>.  1966;163:866.</li>
<li>Gaar KA Jr, Taylor AE, Owens LJ, Guyton AC.  <span class="Italics">Amer. J. Physiol</span>.  1967;213:79.</li>
<li>Heughan C, Niinikoski J, Hunt TK.  <span class="Italics">Surg. Gynec. Obstet</span>.  1972;135:257.</li>
<li>Hoye RC, Paulson DF, Ketcham AS.  <span class="Italics">Surg. Gynec. Obstet</span>.  1970;131:943.</li>
<li>Kinney JM, Egdahl RH, Zuidema GD.  <span class="Italics">Manual of Preoperative and Postoperative Care, American College of Surgeons</span>.  Philadelphia:  W. B. Saunders Co; 1971.</li>
<li>Lowenstein E.  In: Sgouris JT, René A, ed.  <span class="Italics">Proceedings of the Workshop on Albumin, February 12–13</span>.  Bethesda, Maryland 20014:  DHEW Publication NIH 76-925, NHLI;  p. 302, 1975.</li>
<li>Moss G.  <span class="Italics">Surg. Forum</span>.  1967;18:333.</li>
<li>Pappova E, Bachmeier W, Crevoisier JL, Kollar J, Kollar M, Tobler P, Zahler HW, Zaugg D, Lundsgaard-Hansen P.  <span class="Italics">Vox Sang</span>.  1977;33:307.</li>
<li>Ring J, Messmer K.  <span class="Italics">Lancet</span>.  1977;1:466.</li>
<li>Ring J, Seifert J, Lob G, Coulin K, Brendel W.  <span class="Italics">Klin. Wschr</span>. 1974;52:595.</li>
<li>Sgouris JT, René A, ed.  <span class="Italics">Proceedings of the Workshop on Albumin, February 12–13</span>.  Bethesda, Maryland 20014:  DHEW Publication NIH 76-925, NHLI; 1975.</li>
<li>Skillman JJ, Parikh BM, Tanenbaum BJ.  <span class="Italics">Amer. J. Surg</span>.  1970;119:440.</li>
<li>Skillman JJ, Tanenbaum BJ.  <span class="Italics">Current Topics in Surgical Research</span>.  New York:  Academic Press; 1970;2:523.</li>
<li>Starling EH.  <span class="Italics">J. Physiol</span>.  1896;19:312-326.</li>
<li>Tullis JL.  <span class="Italics">JAMA</span>.  1977;237:355,460.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Manufactured by:<br><span class="Bold">CSL Behring AG</span><br>Bern, Switzerland<br>US License No. 1766</p>
<p>Distributed by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901 USA</p>
<p>Revised September 2014</p>
<p>2771/962</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>Principal Display Panel - 50 mL Vial Label</h1>
<p class="First"><span class="Bold">NDC 44206-251-90</span></p>
<p><span class="Bold">25%</span></p>
<p><span class="Bold">50 mL</span></p>
<p><span class="Bold">Albumin (Human) 25% Solution</span><br><span class="Bold">AlbuRx</span><span class="Sup">®</span><span class="Bold"> 25</span></p>
<p><span class="Bold">Contains:</span> 12.5 g Albumin (Human) in 50 mL of buffered diluent. Stabilized with <br>0.02 M sodium caprylate and 0.02 M sodium N-acetyltryptophanate. Osmotically <br>equivalent to 250 mL of plasma. Sodium content is 0.14 M.</p>
<p><span class="Bold">Caution: </span>DO NOT USE IF TURBID. DO NOT BEGIN ADMINISTRATION MORE THAN <br>4 HOURS AFTER THE CONTAINER HAS BEEN ENTERED.</p>
<p>In the presence of marked <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, additional fluids must accompany or follow the <br>administration of albumin. Contains no preservative. Store at temperature not exceeding <br>30°C (86°F). The patient and physician should discuss the risks and benefits of this product.</p>
<p>See package insert for directions for use and product dosage information. <span class="Bold">Rx only</span></p>
<p>Manufactured by:<br><span class="Bold">CSL Behring AG</span><br>Bern, Switzerland<br>US License No. 1766</p>
<p>Distributed by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901<br>USA</p>
<p>2762/960</p>
<div class="Figure"><img alt="Principal Display Panel - 50 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad74b7f5-b380-47ab-b19d-eef92c8eb7a4&amp;name=alburx-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>Principal Display Panel - 50 mL Vial Carton</h1>
<p class="First"><span class="Bold">NDC 44206-251-05</span></p>
<p><span class="Bold">25%</span></p>
<p><span class="Bold">50 mL</span></p>
<p><span class="Bold">Albumin (Human)<br>25% Solution</span><br><span class="Bold">AlbuRx</span><span class="Sup">®</span><span class="Bold"> 25</span></p>
<p><span class="Bold">For intravenous<br>administration</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">CSL Behring</span></p>
<div class="Figure"><img alt="Principal Display Panel - 50 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad74b7f5-b380-47ab-b19d-eef92c8eb7a4&amp;name=alburx-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALBURX 		
					</strong><br><span class="contentTableReg">albumin (human) solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:44206-251</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALBUMIN HUMAN</strong> (ALBUMIN HUMAN) </td>
<td class="formItem">ALBUMIN HUMAN</td>
<td class="formItem">12.5 g  in 50 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium acetyltryptophanate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium caprylate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:44206-251-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:44206-251-90</td>
<td class="formItem">50 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:44206-251-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:44206-251-91</td>
<td class="formItem">100 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA102366</td>
<td class="formItem">01/06/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>CSL Behring AG
							(481152762)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">CSL Behring AG</td>
<td class="formItem"></td>
<td class="formItem">481152762</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fec81c2b-a685-4b25-b4c0-9e52c2f44e9f</div>
<div>Set id: ad74b7f5-b380-47ab-b19d-eef92c8eb7a4</div>
<div>Version: 5</div>
<div>Effective Time: 20150825</div>
</div>
</div> <div class="DistributorName">CSL Behring AG</div></p>
</body></html>
